These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36651068)

  • 1. COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues.
    Chirap-Mitulschi IA; Ghimus C; Chirap-Mitulschi AR; Antoniu SA; Dragomir R
    Drugs Today (Barc); 2022 Dec; 58(12):605-620. PubMed ID: 36651068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
    Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis.
    Wu X; Wang L; Shen L; Tang K
    EBioMedicine; 2022 Jul; 81():104102. PubMed ID: 35759920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
    Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
    EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
    Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
    CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
    Centonze D; Rocca MA; Gasperini C; Kappos L; Hartung HP; Magyari M; Oreja-Guevara C; Trojano M; Wiendl H; Filippi M
    J Neurol; 2021 Nov; 268(11):3961-3968. PubMed ID: 33844056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.
    Reder AT; Stuve O; Tankou SK; Leist TP
    Mult Scler; 2023 May; 29(6):648-656. PubMed ID: 36440826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
    Cohen JA; Bermel RA; Grossman CI; Hersh CM; Hyland M; Mowry EM; Naismith R; Naylor ML; Nicholas J; Rajbhandar R; Singh CM; Tintorè M; Zabalza A; Ziemssen T; Williams JR; Montalban X
    Mult Scler; 2022 Jun; 28(7):1131-1137. PubMed ID: 34994577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.
    Garjani A; Patel S; Bharkhada D; Rashid W; Coles A; Law GR; Evangelou N
    Mult Scler Relat Disord; 2022 Jan; 57():103458. PubMed ID: 34896876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2).
    Klineova S; Farber RS; DeAngelis T; Leung T; Smith T; Blanck R; Zhovtis-Ryerson L; Harel A
    Mult Scler; 2023 Jul; 29(8):990-1000. PubMed ID: 37431628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study.
    Idda ML; Pitzalis M; Lodde V; Loizedda A; Frau J; Lobina M; Zoledziewska M; Virdis F; Delogu G; Marini MG; Mingoia M; Masala M; Lorefice L; Fronza M; Carmagnini D; Carta E; Pilotto S; Castiglia P; Chessa P; Uzzau S; Farina G; Solla P; Steri M; Devoto M; Fiorillo E; Floris M; Zarbo RI; Cocco E; Cucca F
    Front Immunol; 2022; 13():946356. PubMed ID: 36059537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in.
    Pugliatti M; Hartung HP; Oreja-Guevara C; Pozzilli C; Airas L; Alkhawajah M; Grigoriadis N; Magyari M; Van Wijmeersch B; Zakaria M; Linker R; Chan A; Vermersch P; Berger T
    Front Immunol; 2022; 13():1045101. PubMed ID: 36325318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis.
    Pernicová E; Macounová P; Krsek M; Maďar R
    Eur Neurol; 2023; 86(4):263-276. PubMed ID: 36871554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies.
    Wallach AI; Schiebel M; Picone MA
    Mult Scler Relat Disord; 2022 Jul; 63():103856. PubMed ID: 35636275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of disease-modifying therapies on humoral and cellular immune-responses following SARS-CoV-2 vaccination in MS patients.
    Trümpelmann S; Schulte-Mecklenbeck A; Steinberg OV; Wirth T; Fobker M; Lohmann L; Lünemann JD; Wiendl H; Gross CC; Klotz L
    Clin Transl Sci; 2022 Jul; 15(7):1606-1612. PubMed ID: 35213793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
    Zabalza A; Arrambide G; Otero-Romero S; Pappolla A; Tagliani P; López-Maza S; Cárdenas-Robledo S; Esperalba J; Fernández-Naval C; Martínez-Gallo M; Castillo M; Bonastre M; Resina-Salles M; Bertran J; Rodriguez-Barranco M; Carbonell-Mirabent P; Gonzalez M; Merchan M; Quiroga-Varela A; Miguela A; Gómez I; Álvarez G; Robles R; Perez Del Campo D; Queralt X; Soler MJ; Agraz I; Martinez-Valle F; Rodríguez-Acevedo B; Midaglia L; Vidal-Jordana Á; Cobo-Calvo Á; Tur C; Galan I; Castillo J; Río J; Espejo C; Comabella M; Nos C; Sastre-Garriga J; Ramió-Torrentà L; Tintoré M; Montalban X
    Mult Scler; 2022 Jun; 28(7):1138-1145. PubMed ID: 35475363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies.
    Allman M; Tallantyre E; Robertson NP
    J Neurol; 2022 Apr; 269(4):2259-2261. PubMed ID: 35286479
    [No Abstract]   [Full Text] [Related]  

  • 18. Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.
    Räuber S; Willison A; Korsen M; Kölsche T; Golombeck KS; Plaack B; Schüller J; Huntemann N; Rolfes L; Schroeter CB; Nelke C; Regner-Nelke L; Förster M; Ringelstein M; Barnett MH; Hartung HP; Aktas O; Albrecht P; Ruck T; Melzer N; Meuth SG; Kremer D
    Front Immunol; 2022; 13():1037214. PubMed ID: 36618356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose.
    Dreyer-Alster S; Menascu S; Mandel M; Shirbint E; Magalashvili D; Dolev M; Flechter S; Givon U; Guber D; Stern Y; Miron S; Polliack M; Falb R; Sonis P; Gurevich M; Achiron A
    J Neurol Sci; 2022 Mar; 434():120155. PubMed ID: 35091386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
    Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
    Front Immunol; 2022; 13():868915. PubMed ID: 35432335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.